辅舒酮预防婴幼儿毛细支气管炎后哮喘的疗效观察  

Flixotide Decreased the Incidence of Asthma Following Bronchiolitis

作　　者：宋文辉[1] 江文胜[1] 黄旭升[1] 

机构地区：[1]皖南医学院附属安徽省铜陵市人民医院儿科,244000

出　　处：《医学研究杂志》2008年第7期80-81,共2页Journal of Medical Research

摘　　要：目的观察吸入辅舒酮能否减少婴幼儿毛细支气管炎后哮喘的发生率。方法将52例毛细支气管炎患儿随机分为两组,观察组23例采用辅舒酮吸入预防,疗程为2个月;对照组29例则不用药预防。临床随访半年、1年,观察两组患儿哮喘的发生率。结果完成1年以上随访者,观察组仅3例(13.04%)发生哮喘,对照组中则有24例(82.76%)发生哮喘,两组比较有显著性差异(P<0.01)。结论吸入辅舒酮可明显降低婴幼儿毛细支气管炎后哮喘的患病率。Objective To evaluate the efficiency of Flixotide in decreasing the incidence of asthma following bronchiolitis. Methods 23 children with brochiolitis received Flixotide daily while other 29 subjects not intervented as control. The intervention duration was 60 days, then followed up for more then 1 year. Results After following up over 1 year, only 3 cases in 29 patients with brochiolitis receiving Flixotide developed into asthma. However, 24 cases in control group developed into asthma. The incidence of asthma was 13.04% and 82.76% in two group, respectively. Conclusion Flixotide may be an effective intervention to prevent the development of asthma after bronchiolitis.

关 键 词：毛细支气管炎 哮喘 辅舒酮 

分 类 号：R562.21[医药卫生—呼吸系统] R725.622.5[医药卫生—内科学]